• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: pegcetacoplan
Trade Name: Empaveli
Date Designated: 12/19/2018
Orphan Designation: Treatment of C3 glomerulopathy
Orphan Designation Status: Designated/Approved
Apellis Pharmaceuticals, Inc., a wholly owned subsidiary of Biogen, MA, Inc.
100 5th Avenue, 3rd Floor
Waltham, Massachusetts 02451
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: pegcetacoplan
Trade Name: Empaveli
Marketing Approval Date: 07/28/2025
Approved Labeled Indication: treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuria
Exclusivity End Date: 07/28/2032 
Exclusivity Protected Indication* :  treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuria
2 Generic Name: pegcetacoplan
Trade Name: Empaveli
Marketing Approval Date: 08/20/2026
Approved Labeled Indication: treatment of adult and pediatric patients aged 12 years and older with C3 glomerulopathy (C3G), to reduce proteinuria and the loss of kidney function
Exclusivity End Date: TBD  

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-